RE: Volume bid offer tight23 Mar 2025 08:06
In my opinion this type of advancement in medicine come round once every 10 or 20 years. It has ‘potential’ to change the whole medical field and provide further insides to combatting other inflammatory responses in the body. Hundreds of millions is small money for big pharmas so I wouldn’t be surprised to see £1per share at all. Big pharma will want to own this asap. I’m not a fan of big pharma and synthetic drugs at all as I think you have to work with the body from the inside out to cure or reduce symptoms, not just cover them up.
The body is like a car, when an engine management light comes on, taking the bulb out of the warning light doesn’t fix the problem and will no doubt cause more serious implications further down the line that require more work.
My point being is big pharma will either want to own this outright to take to market themselves, or they will want to own it to protect their sales on the synthetic side of ‘treatment’.
£1 per share or around £400m buy out is more than doable for them in this scenario.